These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
165 related articles for article (PubMed ID: 20818441)
1. A pilot study of reduced toxicity conditioning with BU, fludarabine and alemtuzumab before the allogeneic hematopoietic SCT in children and adolescents. Styczynski J; Tallamy B; Waxman I; van de Ven C; Milone MC; Shaw LM; Harrison L; Morris E; Satwani P; Bhatia M; George D; Bradley MB; Garvin JH; Schwartz J; Baxter-Lowe LA; Cairo MS Bone Marrow Transplant; 2011 Jun; 46(6):790-9. PubMed ID: 20818441 [TBL] [Abstract][Full Text] [Related]
2. Busulfan, fludarabine, and alemtuzumab as a reduced toxicity regimen for children with malignant and nonmalignant diseases improves engraftment and graft-versus-host disease without delaying immune reconstitution. Law J; Cowan MJ; Dvorak CC; Musick L; Long-Boyle JR; Baxter-Lowe LA; Horn B Biol Blood Marrow Transplant; 2012 Nov; 18(11):1656-63. PubMed ID: 22609040 [TBL] [Abstract][Full Text] [Related]
3. A pilot study of reduced intensity conditioning and allogeneic stem cell transplantation from unrelated cord blood and matched family donors in children and adolescent recipients. Del Toro G; Satwani P; Harrison L; Cheung YK; Brigid Bradley M; George D; Yamashiro DJ; Garvin J; Skerrett D; Bessmertny O; Wolownik K; Wischhover C; van de Ven C; Cairo MS Bone Marrow Transplant; 2004 Mar; 33(6):613-22. PubMed ID: 14730337 [TBL] [Abstract][Full Text] [Related]
4. Allogeneic peripheral blood stem cell transplantation using a fludarabine-based low intensity conditioning regimen for malignant lymphoma. Nagler A; Slavin S; Varadi G; Naparstek E; Samuel S; Or R Bone Marrow Transplant; 2000 May; 25(10):1021-8. PubMed ID: 10828860 [TBL] [Abstract][Full Text] [Related]
5. Reduced toxicity, myeloablative conditioning with BU, fludarabine, alemtuzumab and SCT from sibling donors in children with sickle cell disease. Bhatia M; Jin Z; Baker C; Geyer MB; Radhakrishnan K; Morris E; Satwani P; George D; Garvin J; Del Toro G; Zuckerman W; Lee MT; Licursi M; Hawks R; Smilow E; Baxter-Lowe LA; Schwartz J; Cairo MS Bone Marrow Transplant; 2014 Jul; 49(7):913-20. PubMed ID: 24797180 [TBL] [Abstract][Full Text] [Related]
6. Engraftment kinetics and hematopoietic chimerism after reduced-intensity conditioning with fludarabine and treosulfan before allogeneic stem cell transplantation. Blau IW; Schmidt-Hieber M; Leschinger N; Göldner H; Knauf W; Hopfenmüller W; Thiel E; Blau O Ann Hematol; 2007 Aug; 86(8):583-9. PubMed ID: 17468869 [TBL] [Abstract][Full Text] [Related]
7. Allogeneic stem cell transplantation after a fludarabine/busulfan-based reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia. Kröger N; Bornhäuser M; Ehninger G; Schwerdtfeger R; Biersack H; Sayer HG; Wandt H; Schäfer-Eckardt K; Beyer J; Kiehl M; Zander AR; Ann Hematol; 2003 Jun; 82(6):336-42. PubMed ID: 12728337 [TBL] [Abstract][Full Text] [Related]
8. Establishment of early donor engraftment after reduced-intensity allogeneic hematopoietic stem cell transplantation to potentiate the graft-versus-lymphoma effect against refractory lymphomas. Bishop MR; Hou JW; Wilson WH; Steinberg SM; Odom J; Castro K; Kasten-Sportes C; Gea-Banacloche J; Marchigiani D; Gress R; Fowler DH Biol Blood Marrow Transplant; 2003 Mar; 9(3):162-9. PubMed ID: 12652466 [TBL] [Abstract][Full Text] [Related]
9. Fludarabine vs cladribine plus busulfan and low-dose TBI as reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation: a prospective randomized trial. Markova M; Barker JN; Miller JS; Arora M; Wagner JE; Burns LJ; MacMillan ML; Douek D; DeFor T; Tan Y; Repka T; Blazar BR; Weisdorf DJ Bone Marrow Transplant; 2007 Feb; 39(4):193-9. PubMed ID: 17220905 [TBL] [Abstract][Full Text] [Related]
10. Non-TBI stem cell transplantation protocol for Fanconi anaemia using HLA-compatible sibling and unrelated donors. de la Fuente J; Reiss S; McCloy M; Vulliamy T; Roberts IA; Rahemtulla A; Dokal I Bone Marrow Transplant; 2003 Oct; 32(7):653-6. PubMed ID: 13130311 [TBL] [Abstract][Full Text] [Related]
11. Hematopoietic cell transplantation from an HLA-mismatched familial donor is feasible without ex vivo-T cell depletion after reduced-intensity conditioning with busulfan, fludarabine, and antithymocyte globulin. Lee KH; Lee JH; Lee JH; Kim DY; Kim SH; Shin HJ; Lee YS; Kang YA; Seol M; Ryu SG Biol Blood Marrow Transplant; 2009 Jan; 15(1):61-72. PubMed ID: 19135944 [TBL] [Abstract][Full Text] [Related]
12. Prospective phase II trial to evaluate the complications and kinetics of chimerism induction following allogeneic hematopoietic stem cell transplantation with fludarabine and busulfan. Saito AM; Kami M; Mori S; Kanda Y; Suzuki R; Mineishi S; Takami A; Taniguchi S; Takemoto Y; Hara M; Yamaguchi M; Hino M; Yoshida T; Kim SW; Hori A; Ohashi Y; Takaue Y Am J Hematol; 2007 Oct; 82(10):873-80. PubMed ID: 17570513 [TBL] [Abstract][Full Text] [Related]
13. Substitution of cyclophosphamide and busulfan by fludarabine, treosulfan and melphalan in a preparative regimen for children and adolescents with Shwachman-Diamond syndrome. Sauer M; Zeidler C; Meissner B; Rehe K; Hanke A; Welte K; Lohse P; Sykora KW Bone Marrow Transplant; 2007 Feb; 39(3):143-7. PubMed ID: 17211437 [TBL] [Abstract][Full Text] [Related]